US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Latigo Biotherapeutics / Equity Capital Markets

<ul>
<li>Non-Opioid pain pioneer: Latigo is advancing Nav1.8 inhibitors designed to provide effective pain relief without opioid-related addiction risks across acute and chronic pain markets.</li>
<li>IPO funds clinical expansion: Proceeds will support Phase 3 development of LTG-001, advancing LTG-321, and expanding Latigo’s broader pain therapeutic pipeline.</li>
<li>Lead candidate shows promise: LTG-001 delivered positive Phase 2 data, reducing pain rapidly while demonstrating opioid-sparing potential in postoperative pain patients.</li>
</ul>


Non-Opioid pain pioneer: Latigo is advancing Nav1.8 inhibitors designed to provide effective pain relief without opioid-related addiction risks across acute and chronic pain markets.
IPO funds clinical expansion: Proceeds will support Phase 3 development of LTG-001, advancing LTG-321, and expanding Latigo’s broader pain therapeutic pipeline.
Lead candidate shows promise: LTG-001 delivered positive Phase 2 data, reducing pain rapidly while demonstrating opioid-sparing potential in postoperative pain patients.


Latigo Biotherapeutics (LTGO): Biotech Sets IPO Terms Behind Non-Opioid Pain Pipeline

United States

Latigo Biotherapeutics, Inc. is a biopharmaceutical company. The Company develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Latigo Biotherapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Latigo Biotherapeutics (LTGO US)

Latigo Biotherapeutics (LTGO): Biotech Sets IPO Terms Behind Non-Opioid Pain Pipeline

Latigo is developing non-opioid pain treatments to address acute and chronic pain markets, with promising Phase 2 data showing effectiveness and...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Latigo Biotherapeutics (LTGO): Biotech Sets IPO Terms Behind Non-Opioid Pain Pipeline

​Latigo is developing non-opioid pain treatments to address acute and chronic pain markets, with promising Phase 2 data showing effectiveness and...

IPO Boutique

Latigo is developing non-opioid pain treatments to address acute and chronic pain markets, with promising Phase 2 data showing effectiveness and...